Simeprevir approved in the European Union for the treatment

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

May 16, 2014 at 7:15 AM

Simeprevir approved in the European Union for the treatment of adults with hepatitis C genotype 1 and 4 infection

· OLYSIO™ (Simeprevir) provides a new triple therapy treatment option, as well as the first ever 12-week interferon-free and ribavirin independent treatment regimen, in combination with sofosbuvir, for appropriate patients in Europe Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that simeprevir has been granted marketing authorisation by the European Commission (EC) for the treatment of adults with genotype 1 and 4 chronic hepatitis C in combination with other medicinal products. “The approval of simeprevir in Europe is a further step in our partner's global strategy to enable an improved treatment for hepatitis C patients. This also means that Medivir will now be able to offer this treatment to patients in the Nordic region, where we have the marketing rights“, says Maris Hartmanis, CEO, Medivir. This marketing authorisation represents a significant milestone in the development of new triple therapy hepatitis C (HCV) treatment options for genotype 1 and 4 patients. It also includes simeprevir as part of an all oral 12 -week interferon-free direct-acting antiviral (DAA) regimen with or without ribavirin (RBV), in genotype 1 or 4 patients, who are intolerant to or ineligible for IFN treatment. [image] * Treatment-naïve and prior relapse patients with cirrhosis who are co-infected with HIV should receive 48 weeks of treatment. Treatment with simeprevir must be initiated in combination with PegIFN + RBV and administered for 12 weeks and then followed by an additional 36 weeks of PegIFN + RBV. The EC approval for simeprevir with PegIFN + RBV is based on a clinical trial programme involving three pivotal phase III studies, with over 1000 patients. The trials; QUEST-1, QUEST-2 and PROMISE, explored the use of simeprevir in combination with PegIFN/RBV in treatment-naïve patients and patients who have relapsed after prior interferon-base treatment. All three studies met their primary endpoints and demonstrated that simeprevir in combination with PegIFN/RBV, achieves significant cure rates when compared with PegIFN/RBV alone. The EC approval for the combination of simeprevir and sofosbuvir also contains the phase II study, COSMOS. This was based upon prior null responder and treatment-naïve patients. For more information please contact: Rein Piir, EVP Corporate Affairs & IR, mobile: +46 708 537 292 Medivir is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 13.00 CET on 16 May 2014. About Simeprevir Simeprevir is an NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB and indicated for the treatment chronic hepatitis C infection in combination with pegylated interferon and ribavirin in HCV genotype 1 and 4 infected patients with compensated liver disease, including cirrhosis. Janssen is responsible for the global clinical development of simeprevir and has exclusive, worldwide marketing rights, except in the Nordic countries. Medivir AB retains marketing rights for simeprevir in these countries under the marketing authorization held by Janssen-Cilag International NV. Simeprevir was approved for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis in September 2013 in Japan, in November 2013 in Canada and the U.S. and in March 2014 in Russia. Following the EMA approval, it is anticipated that simeprevir will be available across a number of European Union countries in conjunction with reimbursement, in the second half of 2014. About Medivir Medivir is an emerging research-based pharmaceutical company focused on infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company’s key pipeline asset is simeprevir, a novel protease inhibitor for the treatment of hepatitis C that is being developed in collaboration with Janssen R&D Ireland. The company is also working with research and development in other areas, such as bone disorders and neuropathic pain. Medivir has also a broad product portfolio with prescription pharmaceuticals in the Nordics.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Adam Foundation's Ramadan Effort to Cut Plastic Waste

Environmental Consciousness: A Call from Antalya Here we go again, folks. Something refreshing is brewing over in Antalya at COP31, where the UK-based Adam Foundation has made a move that resonates beyond the usual hubbub. No smoke and mirrors, just straightforward action aimed at cutting down the wave of plastic waste during Ramadan. This isn't some pie-in-the-sky green...

Positron AI's Strategic Moves Garner Top Recognition

Breaking Barriers in AI Hardware When a tech firm starts making waves in the AI sphere, ears perk up. Positron AI, with its focus on making AI inference not only feasible but profitable and scalable, finds itself freshly minted on the esteemed 2026 AI 100 list. This isn’t just a little pat on the back; it's a nod from the industry's watchful gaze. Momentum Backed by...

CytoSorbents Hits Financial Milestone in Q3 2026

CytoSorbents' Financial Turnaround Imagine the smell of fresh opportunity wafting through CytoSorbents’ (NASDAQ:CTSO) corridors this quarter. The company just nudged into positive territory with its operating cash flow, which, let’s be honest, is like finding a nugget of gold amid last year’s rubble of losses. With $43,000 of positive operating cash flow in a world...

FDA Greenlights AI for Brain Aneurysm Detection

Unveiling UPTUNITY: A New AI Solution Well, ain't that something? Bracco and Avicenna.AI just got the FDA's nod for their latest creation, UPTUNITY. It's like giving radiologists a trusty sidekick to spot those sneaky brain aneurysms. This ain't just another gizmo; it's a game-changer in medical imaging, giving AI a real shot at transforming how these medical sleuths do...

NJ Water Boosts Fire & EMS Grants to $5K in 2027

Water Utility Backs First Responders with Bigger Bucks Listen up, folks. The New Jersey American Water company just threw down the gauntlet with some bold moves for its 2027 Volunteer Fire and EMS Grant Program. They've taken the maximum grant amount from $2,500 to $5,000. Yeah, you heard right. Doubling the pot and starting the application cycle earlier means volunteer...

Veterans Guardian Earns 2026 Gold HIRE Vets Medallion

Veterans Guardian Celebrates Another Milestone Alright, folks, let me hit you with a piece of news that didn't just skim across the ticker like another stock price—this one's truly for the soul. Veterans Guardian VA Claim Consulting out of Pinehurst, North Carolina, snagged the 2026 Gold HIRE Vets Medallion Award from the U.S. Department of Labor. It's a nod that goes...

Zinzino's 2027 Nomination Committee Prepares for AGM

Unveiling Zinzino's New Nomination Committee Ah, Gothenburg—the city known for its beautiful canals and now, yet another lineup change for Zinzino AB's Nomination Committee. This is part and parcel of the games companies play before their Annual General Meetings (AGM) and generally an indicator of either stasis or shifts ahead. The names on the roster for Zinzino’s...

Avoid Costly Checking Account Mistakes: Key Tips

Oversights That Could Drain Your Wallet Let me tell you, folks skip over their checking account details like it's a doctor's recommended veggie list. Even seasoned bankers trip up on the regular. Banking Expert Trent Nelson of PriorityOne Bank spills the beans on how understanding your account could save you from costly missteps and keep unnecessary fees at bay. Turns...

Pet Supplies Plus Celebrates Success in Customer Service

Acknowledging Excellence in Retail Service You don't often see a pet store at the top of such elite lists, but Pet Supplies Plus has managed exactly that. Ranked number one in its category for both customer service and franchise performance, they've set a benchmark others ought to take note of. We’re talking number 41 on Forbes' Best Customer Service list and number 51...

Newsday Unveils Essential Guide to NY Colleges

Launching a Comprehensive College Resource Ah, the college decision stress. Back in the day it was simpler, just pick a campus that looked good on paper and hope for the best. But now? Kids and their families have got a minefield of information to navigate. Time to make room at the table for Newsday's latest attempt to unravel the college chaos with their Essential Guide...